Skip to content
sellWeak cluster of 6

Paul F. Lizzul sold $183k of ANAB

Chief Medical Officer at ANAPTYSBIO, INC. 4,219 shares at an average of $43.26, traded Jan 5, 2026, filed Jan 6, 2026.

Warning score
32
Value
$183k
4,219 shares
Holdings after
33,303
-11% from before
From 52-week low
+249%
low $8.25, close $28.80
From 52-week high
-15%
high $33.94, as of Jan 5, 2026

Score components

  • Role
    Officer
    +15
  • Trade size
    $183k at market
    +12
  • Share of holdings sold
    Sold 11% of holdings
    +5
  • Cluster
    6 insiders selling within 14 days
    +15
  • Exercise and sell
    Shares came from an option exercise in the same filing
    -15

What happened after comparable sells

Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.

This signal so far: 1m +9.1%, 3m +41.5%, 6m +130.0%.

Price around the trade, and since

From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.

ANABOct 13, 2026 · close 45.59
Since filing Jan 6, 2026: +55.7%SPY +13.3% · excess +42.4%

Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™

Rows in this filing

Every transaction in Form 4 0001711462-26-000002, as filed. Open on EDGAR

DateTransactionSharesPriceValueHoldings afterFiled
Jan 3, 2026MOption exercise
Common Stock
+10,555--37,522Jan 6, 2026
Jan 5, 2026SOpen-market sale
Common Stock
-4,219$43.26$183k33,303Jan 6, 2026
Jan 3, 2026MOption exercise
Restricted Stock Unitderivative
-10,555$0.00$021,110Jan 6, 2026

Related signals

Other insiders at ANAPTYSBIO, INC and this insider’s other filings.

ScoreCompanyInsiderValueHoldingsFiled
3Weak
ANABsell10b5-1
ANAPTYSBIO, INC
Hollings Renton
director
$249k
5,000 shares
-31%
58Moderate
ANABsell 2
ANAPTYSBIO, INC
John P. Schmid
director
$1.2M
20,645 shares
-39%
58Moderate
ANABsell 2
ANAPTYSBIO, INC
Daniel Faga
President, CEO
$1.1M
17,679 shares
-3%
9Weak
ANABsell10b5-1
ANAPTYSBIO, INC
Eric J Loumeau
CHIEF LEGAL OFFICER
$540k
10,000 shares
-44%
53Moderate
ANABsell 5
ANAPTYSBIO, INC
Magda Marquet
director
$531k
11,000 shares
-53%
30Weak
ANABsell 5
ANAPTYSBIO, INC
Eric J Loumeau
CHIEF LEGAL OFFICER
$99k
2,210 shares
-15%
37Weak
ANABsell 5
ANAPTYSBIO, INC
Dennis Mulroy
CHIEF FINANCIAL OFFICER
$112k
2,515 shares
-10%
45Moderate
ANABsell 5
ANAPTYSBIO, INC
Daniel Faga
President, CEO
$639k
14,281 shares
-3%
26Weak
ANABsell 5
ANAPTYSBIO, INC
Paul F. Lizzul
Chief Medical Officer
$163k
3,650 shares
-8%
32Weak
ANABsell 510b5-1
ANAPTYSBIO, INC
Eric J Loumeau
CHIEF LEGAL OFFICER
$439k
9,639 shares
-51%

Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.

Paul F. Lizzul sold $183k of ANAB | InsiderTell